These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


208 related items for PubMed ID: 3859217

  • 21. Piperacillin or ticarcillin plus amikacin. A double-blind prospective comparison of empiric antibiotic therapy for febrile granulocytopenic cancer patients.
    Wade JC, Schimpff SC, Newman KA, Fortner CL, Standiford HC, Wiernik PH.
    Am J Med; 1981 Dec; 71(6):983-90. PubMed ID: 6459027
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Antibacterial activity of imipenem: the first thienamycin antibiotic.
    Kropp H, Gerckens L, Sundelof JG, Kahan FM.
    Rev Infect Dis; 1985 Dec; 7 Suppl 3():S389-410. PubMed ID: 3931196
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Cefotaxime plus amikacin as empiric therapy in the treatment of febrile episodes in neutropenic patients with hematologic malignancies.
    Martino P, Venditti M, Petti MC, Mandelli F, Serra P.
    Infection; 1985 Dec; 13(3):125-9. PubMed ID: 3928495
    [Abstract] [Full Text] [Related]

  • 31. The in-vivo postantibiotic effect of imipenem and other new antimicrobials.
    Gudmundsson S, Vogelman B, Craig WA.
    J Antimicrob Chemother; 1986 Dec; 18 Suppl E():67-73. PubMed ID: 3469197
    [Abstract] [Full Text] [Related]

  • 32. Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program.
    Ong CT, Kuti JL, Nicolau DP, OPTAMA Program.
    Surg Infect (Larchmt); 2005 Dec; 6(4):419-26. PubMed ID: 16433606
    [Abstract] [Full Text] [Related]

  • 33. Treatment of febrile episodes in neutropenic leukemic patients with the antibiotic combinations piperacillin or ceftazidime plus amikacin: results of a randomized study.
    Fenu S, Raccah R, Santilli S, Micozzi A, Girmena C, Martino P, Avvisati G.
    Chemioterapia; 1988 Oct; 7(5):323-6. PubMed ID: 3066517
    [Abstract] [Full Text] [Related]

  • 34. Antibiotic combinations for the empiric treatment of the febrile neutropenic patient.
    Walsh TJ, Schimpff SC.
    Schweiz Med Wochenschr Suppl; 1983 Oct; 14():58-63. PubMed ID: 6361993
    [Abstract] [Full Text] [Related]

  • 35. A comparison of aztreonam plus vancomycin and imipenem plus vancomycin as initial therapy for febrile neutropenic cancer patients.
    Raad II, Whimbey EE, Rolston KV, Abi-Said D, Hachem RY, Pandya RG, Ghaddar HM, Karl CL, Bodey GP.
    Cancer; 1996 Apr 01; 77(7):1386-94. PubMed ID: 8608520
    [Abstract] [Full Text] [Related]

  • 36. Synergism of the combinations of imipenem plus ciprofloxacin and imipenem plus amikacin against Pseudomonas aeruginosa and other bacterial pathogens.
    Bustamante CI, Drusano GL, Wharton RC, Wade JC.
    Antimicrob Agents Chemother; 1987 Apr 01; 31(4):632-4. PubMed ID: 3111357
    [Abstract] [Full Text] [Related]

  • 37. Imipenem versus targeted therapy in cancer patients.
    Aoun M, Crokaert F, Paesmans M, Autier P, Klastersky J.
    Int J Antimicrob Agents; 1998 Nov 01; 10(4):263-70. PubMed ID: 9916899
    [Abstract] [Full Text] [Related]

  • 38. Empiric therapy of febrile granulocytopenic patients.
    Hopefl AW.
    Am J Hosp Pharm; 1979 Feb 01; 36(2):178-87. PubMed ID: 369364
    [Abstract] [Full Text] [Related]

  • 39. Empiric treatment of infections in neutropenic patients with cancer.
    Klastersky J.
    Rev Infect Dis; 1983 Feb 01; 5 Suppl 1():S21-31. PubMed ID: 6342096
    [Abstract] [Full Text] [Related]

  • 40. Therapy of choice for the empiric treatment of the febrile neutropenic patient.
    Barriere SL.
    Drug Intell Clin Pharm; 1986 Oct 01; 20(10):767-9. PubMed ID: 3769764
    [Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 11.